Type II diabetes mellitus is a metabolic disorder characterized by hyperglycemia and sustained by concurrent features represented by obesity, dyslipidemia, hypertension, hypercoagulation, and oxidative stress. As it possesses a multi-factorial origin, it should be effectively treated by compds. showing not only a long-term hypoglycemic effect, but also a favorable action on the addnl. biochem. pathways involved in both the disorder and its complications. This is why the search for multi-target agents in the anti-diabetic field is increasingly becoming a major pharmaceutical challenge. The aim of this chapter is to provide a survey of existing multi-target agents, both in commerce and under investigation, that are exploited to treat diabetes and its main complications. This will provide new perspectives on existing data and a stimulating starting-point for the development of novel compds., with an improved efficacy in treating this disease.
Multi-target agents for the treatment of type II diabetic disorder: the new challenge in pharmacotherapy
LA MOTTA, CONCETTINA;DA SETTIMO PASSETTI, FEDERICO
2010-01-01
Abstract
Type II diabetes mellitus is a metabolic disorder characterized by hyperglycemia and sustained by concurrent features represented by obesity, dyslipidemia, hypertension, hypercoagulation, and oxidative stress. As it possesses a multi-factorial origin, it should be effectively treated by compds. showing not only a long-term hypoglycemic effect, but also a favorable action on the addnl. biochem. pathways involved in both the disorder and its complications. This is why the search for multi-target agents in the anti-diabetic field is increasingly becoming a major pharmaceutical challenge. The aim of this chapter is to provide a survey of existing multi-target agents, both in commerce and under investigation, that are exploited to treat diabetes and its main complications. This will provide new perspectives on existing data and a stimulating starting-point for the development of novel compds., with an improved efficacy in treating this disease.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
